US EditionPublished • loading... • Updated
Interim Findings for SIR-Spheres Resin Microspheres in Unresectable HCC Strengthen Radioembolization’s Position in Europe
Summary
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
DOORwaY90 study signals strong efficacy and safety for SIR-Spheres in unresectable HCC
This advertorial is sponsored by Sirtex Medical. Alexander Villalobos Interim data from the DOORwaY90 study, a prospective, multicentre, open-label, single-arm trial evaluating SIR-Spheres yttrium-90 (Y-90) resin microspheres (Sirtex) as a first-line option for unresectable hepatocellular carcinoma (HCC), demonstrated strong local tumour control and a well-tolerated safety profile. According to investigator Alexander Villalobos (University of No…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
